[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://www.lyell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 300, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 73, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 82734, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 66, "title": "Interim Principal Financial Officer, Principal Executive Officer, President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1021376, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 54, "title": "Chief Operating Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 750442, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 65, "title": "Founder & Scientific Advisor", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary K. Lee Ph.D.", "age": 48, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark A. Meltz J.D.", "age": 51, "title": "General Counsel & Corporate Secretary", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Tomlin", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Selby", "title": "Senior Vice President of Clinical Development Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 30.78, "open": 31.32, "dayLow": 27.22, "dayHigh": 31.32, "regularMarketPreviousClose": 30.78, "regularMarketOpen": 31.32, "regularMarketDayLow": 27.22, "regularMarketDayHigh": 31.32, "payoutRatio": 0.0, "beta": -0.11, "forwardPE": -34.5, "volume": 133013, "regularMarketVolume": 133013, "averageVolume": 61370, "averageVolume10days": 164280, "averageDailyVolume10Day": 164280, "bid": 23.96, "ask": 42.07, "bidSize": 2, "askSize": 2, "marketCap": 615649792, "fiftyTwoWeekLow": 7.65, "fiftyTwoWeekHigh": 45.0, "allTimeHigh": 396.8, "allTimeLow": 7.65, "priceToSalesTrailing12Months": 15015.849, "fiftyDayAverage": 23.8098, "twoHundredDayAverage": 14.19135, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 339564928, "profitMargins": 0.0, "floatShares": 12171194, "sharesOutstanding": 21243954, "sharesShort": 164482, "sharesShortPriorMonth": 163125, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.0077, "heldPercentInsiders": 0.27643, "heldPercentInstitutions": 0.50103, "shortRatio": 2.74, "shortPercentOfFloat": 0.0093, "impliedSharesOutstanding": 21243954, "bookValue": 17.058, "priceToBook": 1.6989095, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -325660000, "trailingEps": -22.75, "forwardEps": -0.84, "lastSplitFactor": "1:20", "lastSplitDate": 1748822400, "enterpriseToRevenue": 8282.071, "enterpriseToEbitda": -1.842, "52WeekChange": 1.2699115, "SandP52WeekChange": 0.14561749, "quoteType": "EQUITY", "currentPrice": 28.98, "targetHighPrice": 45.0, "targetLowPrice": 12.0, "targetMeanPrice": 29.66667, "targetMedianPrice": 32.0, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 319624000, "totalCashPerShare": 15.064, "ebitda": -184380992, "totalDebt": 44285000, "quickRatio": 10.026, "currentRatio": 10.296, "totalRevenue": 41000, "debtToEquity": 13.456, "revenuePerShare": 0.003, "returnOnAssets": -0.24162, "returnOnEquity": -0.75751, "grossProfits": 41000, "freeCashflow": -79681128, "operatingCashflow": -165015008, "revenueGrowth": -0.559, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -2483.5332, "financialCurrency": "USD", "symbol": "LYEL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "marketState": "CLOSED", "twoHundredDayAverageChangePercent": 1.042089, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-17", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623936600000, "postMarketChangePercent": 0.0, "postMarketPrice": 28.98, "postMarketChange": 0.0, "regularMarketChange": -1.8, "regularMarketDayRange": "27.22 - 31.32", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 61370, "fiftyTwoWeekLowChange": 21.33, "fiftyTwoWeekLowChangePercent": 2.7882352, "fiftyTwoWeekRange": "7.65 - 45.0", "fiftyTwoWeekHighChange": -16.02, "fiftyTwoWeekHighChangePercent": -0.356, "fiftyTwoWeekChangePercent": 126.99115, "earningsTimestamp": 1762981200, "earningsTimestampStart": 1762981200, "earningsTimestampEnd": 1762981200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -22.75, "epsForward": -0.84, "fiftyDayAverageChange": 5.1702003, "fiftyDayAverageChangePercent": 0.2171459, "twoHundredDayAverageChange": 14.78865, "corporateActions": [], "postMarketTime": 1767401372, "regularMarketTime": 1767387602, "exchange": "NMS", "messageBoardId": "finmb_590661061", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -5.84796, "regularMarketPrice": 28.98, "displayName": "Lyell Immunopharma", "trailingPegRatio": null, "__fetch_time": "2026-01-03"}]